Supplementary Material

Table 1 Population pharmacokinetics models integrated into the clinical decision support tool

Study (year)	Factor	Formulations
Abrantes[1] (2017)	VIII	ReFacto, ReFacto AF, Xyntha
Zhang[2] (2017)	VIII	rVIII-SingleChain
Garmann[3] (2017)	VIII	BAY 81–8973
Hazendonk[4] (2016)	VIII	Kogenate FS, Helixate FS, Advate, Recombinate, Refacto AF, Aafact, Hemofil M
Björkman[5] (2009)	VIII	Immunate, Monoclate, Monoclate-P, Octonativ-M, Kogenate, Recombinate, ReFacto
Björkman[6] (2017)	VIII	Advate
Bolon-Larger[7] (2007)	VIII	Not specified (plasma-derived or rDNA factor VIII concentrate)
Suzuki[8] (2016)	IX	Not specified (recombinant factor IX)
Brekkan[9] (2016)	IX	AlphaNine, Factor IX Grifols, Immunine, Octanine, Nanotiv, Preconativ, Mononine
Diao[10] (2014)	IX	Not specified
Björkman and Ahlén[11] (2017)	IX	Replenine-VF, Preconativ, Nanotiv, Mononine, Replenine, Alphanine
Björkman[12] (2017)	IX	Not specified (recombinant factor IX)

Supplement References

1 Abrantes JA, Nielsen EI, Korth-Bradley J, Harnisch L, Jönsson S. Elucidation of factor VIII activity pharmacokinetics: a pooled population analysis in patients with hemophilia a treated with moroctocog alfa. ClinPharmacolTher 2017;102(06):977–988

2 Zhang Y, Roberts J, Tortorici M, et al. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A. J ThrombHaemost 2017;15(06):1106–1114

3 Garmann D, McLeay S, Shah A, Vis P, Maas Enriquez M, Ploeger BA. Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia 2017;23(04):528–537

4 Hazendonk H, Fijnvandraat K, Lock J, et al; "OPTI-CLOT" study group. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. Haematologica 2016;101(10):1159–1169

5 Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J ClinPharmacol 2009;65 (10):989–998

6 Björkman S, Oh M, Spotts G, et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012;119(02):612–618

7 Bolon-Larger M, Chamouard V, Bressolle F, Boulieu R. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A. Ther Drug Monit 2007;29(01):20–26

8 Suzuki A, Tomono Y, Korth-Bradley JM. Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B. Haemophilia 2016;22(05):e359–e366

9 Brekkan A, Berntorp E, Jensen K, Nielsen EI, Jönsson S. Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization. J ThrombHaemost 2016;14(04): 724–732

10 Diao L, Li S, Ludden T, Gobburu J, Nestorov I, Jiang H. Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. ClinPharmacokinet 2014;53(05):467–477

11 Björkman S, Ahlén V. Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis. Eur J ClinPharmacol 2012;68(06): 969–977

12 Björkman S. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. Haemophilia 2013;19(05): 753–757